Phosphagenics’ oxycodone patch found to provide pain relief to racehorses – Proactive…

Phosphagenics Limited www.phosphagenics.com/

Phosphagenics (ASX: POH) is a Melbourne-based biotechnology company. Its core technology is built around the science and application of TPM™ delivery systems.  This system enables transdermal delivery of proven pharmaceutical actives and enhances dermal delivery of pharmaceutical, cosmeceutical and nutraceutical actives.

Phosphagenics’ oxycodone patch found to provide pain relief to racehorses

Wednesday, May 21, 2014 by Proactive Investors

The proof of concept<!--more--/> study was conducted on six thoroughbreds with shin bone soreness arising from injuries in either one or two limbs” width=”350″ /></p>
<p class=The proof of concept study was conducted on six thoroughbreds with shin bone soreness arising from injuries in either one or two limbs

Melbourne-based Phosphagenics‘ (, OTCQX:PPGNY) topical oxycodone patch has provided rapid and effective pain relief when applied to racehorses, a new study has found. 

The proof of concept study was conducted on six thoroughbreds with shin bone soreness arising from injuries in either one or two limbs.

A TPM®/Oxycodone patch was applied daily to each injured limb for ten days.

The study results showed there were no signs of lameness and five horses treated were pain-free within 24 hours following the first patch application.

While the sixth horse was pain-free by the second patch application within 48 hours.

Significantly, pain relief from use of the patch allowed the animals to recover without the enduring stress normally associated with such injuries.

Gastric ulceration is one of the biggest health issues for thoroughbred racehorses according to a recent Racing Victoria report.

The topical nature of the patch’s delivery system means gastric ulceration associated with some systemic drug treatments, such as the NSAID Phenylbutazone, could be eliminated.

Analysis

The racehorse study has demonstrated that a significant new market is opening up for Phosphagenics’ TPM®/Oxycodone patch also in the companion animal market.

Which at 40% of the global $23 billion annual animal health market – is a prize.

The results of the racehorse study are also extremely positive for the use of the patch in the $12 billion annual market for neuropathic pain for humans.

Phosphagenics’ Phase 2 trial of TPM®/Oxycodone for human use is due to commence next quarter.

The racehorse study has positive ramifications for the business development of the TPM®/Oxycodone patch.

We are encouraged by these results in the proof of concept study, and consider it value accretive.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Andrew McCrea’s Research Reports
Sign up to Andrew McCrea’s Research Reports and Receive Latest Research & Flash Trades
Receive Proactive Investors Newsletter, Investor Forum Invites
Receive Proactive Investors Newsletter, Event Invites, Special Stock Notifications

Read More:
Phosphagenics’ oxycodone patch found to provide pain relief to racehorses – Proactive…

Number of Babies Born Addicted to Prescription Painkillers Skyrockets – U.S. News & World Report

The number of infants born addicted to prescription painkillers increased to 13,000 in 2009.

An epidemic similar to that of “crack babies” in the early 90s may be resurfacing, with the number of infants being born addicted to prescription painkillers increasing fivefold since 2000.

According to a new study released Monday, babies born with neonatal abstinence syndrome—exposure to addictive drugs while in the (more…)